Girls with Seizures Due to the c.320A>G Variant in ALG13 Do Not Show Abnormal Glycosylation Pattern on Standard

Bethanny Smith-Packard1, Scott M Myers, Marc S Williams

  • 1Genomic Medicine Institute, Geisinger Health System, 100 N Academy Dr. Mail Stop 26-20, Danville, PA, 17822-2620, USA.

JIMD Reports
|March 4, 2015
PubMed

Insights

A novel variant in the X-linked gene ALG13 causes severe early-onset epilepsy and intellectual disability in girls. This finding highlights a potential position effect mechanism in glycosylation disorders.

Area of Science:

  • Genetics
  • Neuroscience
  • Biochemistry

Background:

  • Early-onset severe epilepsy and intellectual disability often lack a genetic diagnosis despite extensive evaluations.
  • Congenital disorders of glycosylation (CDG) are a group of inherited metabolic diseases affecting protein and lipid glycosylation.

Purpose of the Study:

  • To identify the genetic cause of severe early-onset epilepsy, developmental delay, and intellectual disability in a previously undiagnosed girl.
  • To investigate the role of the X-linked gene ALG13 in a severe neurodevelopmental disorder.

Main Methods:

  • Whole-genome sequencing was performed on the proband.
  • Literature review and analysis of published exome sequencing data were conducted to identify other individuals with variants in ALG13.
  • Clinical data from affected individuals were compiled and analyzed.

Main Results:

  • A pathogenic variant (c.320A->G, p.107N->S) in the X-linked gene ALG13 was identified in the proband.
  • Four additional girls with the identical ALG13 variant were identified, all presenting with early-onset severe epilepsy and intellectual disability.
  • Three of the five girls exhibited visual impairment and possible developmental regression. A boy with an ALG13 variant presented with a severe congenital disorder of glycosylation type I.

Conclusions:

  • The consistent severe phenotype in girls with the identical ALG13 variant suggests a critical position effect, potentially impacting gene function.
  • Normal glycosylation studies in one individual indicate a possible novel pathogenic mechanism beyond typical glycosylation defects, warranting further investigation.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K